Skip to main content
. 2023 Jan 24;11(2):323. doi: 10.3390/biomedicines11020323

Figure 1.

Figure 1

Proposed treatment algorithm following anti-cancer-therapy-induced bullous dermatologic adverse events [24,25]. * Such as etanercept, tocilizumab, methotrexate, dapsone, azathioprine, mycophenolate mofetil, omalizumab, dupilumab, rituximab, or IVIg depending on reaction type.